Treanda maker gets SEC subpoena


According to the pharmaceutical blog Pharmalot, Cephalon, the company that makes Treanda (bendamustine) has become the subject of a Securities and Exchange Commission investigation into possible marketing of the drug in unapproved indications.

Cephalon is already functioning under a Corporate Integrity Agreement after the Justice Department busted them in 2008 for marketing several medications for unapproved indications. Cephalon also paid a few hundred million dollars in fines.

Treanda is currently approved in the treatment of:

- Patients with indolent B-cell non-Hodgkin lymphoma (NHL) that progressed during or within six months of treatment with Rituxan or a Rituxan-containing regimen.
- Patients with chronic lymphocytic leukemia (CLL).

While doctors are free to use drugs off-label, a pharmaceutical company can only market a drug under its approved indications.

Further Reading

NCI: Treanda
Pharmalot entry on Cephalon
From the SEC

LymphomaInfo Social